We are live on ! Find out more
ACM

Asymmetry Capital Management Portfolio holdings

AUM $188M
1-Year Est. Return 44.72%
This Fund
S&P 500
This Quarter Est. Return
+29.83%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$219M
AUM Growth
+$63.7M
Cap. Flow
+$40.8M
Cap. Flow %
18.61%
Top 10 Hldgs %
56.75%
Holding
48
New
14
Increased
17
Reduced
2
Closed
15

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$18.4M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$11.7M
3
BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
+$7.65M
4
BDSX icon
Biodesix
BDSX
+$7.46M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.99M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$12.6M
2
QDEL icon
QuidelOrtho
QDEL
+$8.63M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$8.56M
4
CYTK icon
Cytokinetics
CYTK
+$7.37M
5
ILMN icon
Illumina
ILMN
+$6.32M

Sector Composition

Rank Sector Weight
1 Healthcare 97.93%
2 Financials 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FBRX icon
26
Forte Biosciences
FBRX
$1.57B
$3.09M 1.41%
3,400
+207
+6% +$195K
NCNA
27
NuCana
NCNA
$5.99M
$2.76M 1.26%
123
+20
+19% +$480K
MREO
28
Mereo BioPharma
MREO
$43.5M
$2.65M 1.21%
+739,812
New +$1.85M
ORIC icon
29
Oric Pharmaceuticals
ORIC
$1.41B
$2.27M 1.04%
+67,210
New +$1.93M
WVE icon
30
Wave Life Sciences
WVE
$1.2B
$2.21M 1.01%
+280,924
New +$2.36M
ELDN icon
31
Eledon Pharmaceuticals
ELDN
$284M
$1.23M 0.56%
80,069
+19,574
+32% +$373K
BLSA
32
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$993K 0.45%
+89,135
New +$956K
KALV
33
DELISTED
KalVista Pharmaceuticals
KALV
$891K 0.41%
+46,910
New +$804K
ASND icon
34
Ascendis Pharma A/S
ASND
$16.8B
– –
-81,442
Closed -$12.6M
CALC icon
35
CalciMedica
CALC
$10.4M
– –
-6,583
Closed -$1.17M
CYTK icon
36
Cytokinetics
CYTK
$10.5B
– –
-340,253
Closed -$7.37M
EQ icon
37
Equillium
EQ
$138M
– –
-143,543
Closed -$828K
ILMN icon
38
Illumina
ILMN
$29B
– –
-21,024
Closed -$6.32M
LITS
39
Lite Strategy Inc
LITS
$29.6M
– –
-39,368
Closed -$2.46M
PACB icon
40
Pacific Biosciences
PACB
$357M
– –
-257,044
Closed -$2.54M
QDEL icon
41
QuidelOrtho
QDEL
$938M
– –
-39,314
Closed -$8.63M
RNAC icon
42
Cartesian Therapeutics
RNAC
$265M
– –
-1,845
Closed -$137K
UNH icon
43
UnitedHealth
UNH
$371B
– –
-18,666
Closed -$5.82M
GBT
44
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-155,232
Closed -$8.56M
TPTX
45
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
– –
-36,571
Closed -$3.19M
ATRS
46
DELISTED
Antares Pharma, Inc.
ATRS
– –
-1,194,530
Closed -$3.23M
FSDC
47
DELISTED
FS Development Corp. Class A Common Stock
FSDC
– –
-193,728
Closed -$2.17M
HZNP
48
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-51,995
Closed -$4.04M
1
2

Similar funds

FAC
Forrestal Agricultural Corporation Princeton, New Jersey $183M AUM
SWM
Strategic Wealth Management Kirkland, Washington $202M AUM 9.35% 1-Year Est. Return
MC
MRJ Capital New York $173M AUM 31.99% 1-Year Est. Return
KM
Kylin Management New York $173M AUM 39.51% 1-Year Est. Return
TI
Truehand Inc Strafford, New Hampshire $171M AUM 25.9% 1-Year Est. Return
GC
Grace Capital Quincy, Massachusetts $168M AUM 21.6% 1-Year Est. Return
REMS
Real Estate Management Services $167M AUM 37.69% 1-Year Est. Return
NM
Nokota Management New York $165M AUM

Asymmetry Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Asymmetry Capital Management held 48 positions worth $219M, up 41% from $156M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Asymmetry Capital Management deployed $40.8M of net new capital in Q4 2020, opening 14 new positions and adding to 17 existing holdings. Its largest new stake was Viatris: 1,130,504 shares worth $21.2M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Fate Therapeutics, an estimated $3.89M trimmed.

  • Asymmetry Capital Management's largest Q4 2020 buy was Viatris: 1,130,504 shares worth $21.2M.
  • Asymmetry Capital Management added most to Jazz Pharmaceuticals in Q4 2020, an estimated $11.7M increase.
  • Asymmetry Capital Management's biggest Q4 2020 reduction was Fate Therapeutics, cutting an estimated $3.89M.
  • Asymmetry Capital Management fully exited Ascendis Pharma A/S in Q4 2020, selling an estimated $12.6M.
  • Asymmetry Capital Management's ten largest holdings make up 57% of its $219M portfolio in Q4 2020.
  • Asymmetry Capital Management opened 14 new positions and closed 15 in Q4 2020.
  • Asymmetry Capital Management's portfolio value rose 41% quarter-over-quarter to $219M.

Based on Asymmetry Capital Management's 13F filing for Q4 2020, filed 11 Feb 2021.